DC
BMY.RT

Davenport & Co’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Davenport & Co’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-77,794
Closed -$54K – 867
2020
Q4 		$54K Sell
77,794
-1,399
-2% -$2.98K ﹤0.01% 775
2020
Q3 		$178K Sell
79,193
-9,042
-10% -$25.8K ﹤0.01% 686
2020
Q2 		$316K Sell
88,235
-5,030
-5% -$18.1K ﹤0.01% 541
2020
Q1 		$354K Sell
93,265
-1,361
-1% -$4.48K 0.01% 474
2019
Q4 		$285K Buy
+94,626
New +$246K ﹤0.01% 603

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Davenport & Co's BMY.RT Position: Q1 2021 in Review

Davenport & Co sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 77,794 shares — an estimated $54K sold.

Davenport & Co first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $354K in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Davenport & Co reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Davenport & Co sold 77,794 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $54K.
  • Davenport & Co first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Davenport & Co's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $354K in Q1 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Davenport & Co's 13F filing for Q1 2021, filed 28 Apr 2021.